In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vital Therapies, Inc.

http://vitaltherapies.com/

Latest From Vital Therapies, Inc.

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets

Start-up Insitro will attempt to optimize up to five NASH targets for Gilead under three-year alliance. Catalent buys gene therapy CDMO Paragon for $1.2bn, Boehringer partners with PureTech in GI cancer, while Fibrocell inks gene therapy pact with Castle Creek.

Deals Business Strategies

Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma

New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.

Appointments Asia Pacific

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

Immunic of Germany Set For Nasdaq After Merger With Failed Vital Therapies

The demise of Vital after a crushing late-stage failure has given Immunic the opportunity to cross the Atlantic and grow its business and pipeline.

M & A Immune Disorders
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
UsernamePublicRestriction

Register